Work

The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients

Year: 2012

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v120.21.187.187

Authors: Jan A. Burger, Michael J. Keating, William G. Wierda, Julia Hoellenriegel, Alessandra Ferrajoli, Stefan Faderl, Susan Lerner, Gracy Zacharian, Xuelin Huang, Danelle F. James, Joseph J. Buggy, Hagop M Kantarjian, Susan M. O'Brien

Institutions: The University of Texas MD Anderson Cancer Center, Pharmacyclics (United States)

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2573861971

FWCI: 6.819

Cites:

Cited by: 53

Related to: 10